Home > Journals > Minerva Chirurgica > Past Issues > Minerva Chirurgica 2018 August;73(4) > Minerva Chirurgica 2018 August;73(4):366-77

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW  MANAGING EARLY ESOPHAGEAL CANCER ENDOSCOPICALLY 

Minerva Chirurgica 2018 August;73(4):366-77

DOI: 10.23736/S0026-4733.18.07783-0

Copyright © 2018 EDIZIONI MINERVA MEDICA

language: English

Radiofrequency ablation for Barrett’s esophagus-related neoplasia

Jana KRAJCIOVA 1 , Zuzana VACKOVA 1, Julius SPICAK 1, Jan MARTINEK 1, 2, 3

1 Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; 2 Institute of Physiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic; 3 Ostrava University, Faculty of Medicine, Ostrava, Czech Republic


PDF


Barrett’s esophagus (BE) is a premalignant condition associated with increased risk of developing esophageal adenocarcinoma. In the past, BE patients with high-grade intraepithelial neoplasia (IEN) or early adenocarcinoma (EAC) were indicated for esophagectomy. With the recent advance in endoscopy, endoscopic techniques have surpassed esophagectomy in the treatment of Barrett’s esophagus-related neoplasia and minimized the treatment-related morbidity. Patients with IEN are candidates for endoscopic treatment - endoscopic mucosal resection (ER) of visible lesions and/or ablation therapy of flat Barrett’s mucosa. ER combined with radiofrequency ablation (RFA) is now considered as a gold standard for treatment of patients with early Barrett’s cancer. RFA is currently the most effective method of ablation used in the treatment of low-grade intraepithelial neoplasia/high-grade intraepithelial neoplasia without visible lesions and for ablation of residual Barrett’s mucosa following ER/ESD of EAC or HGIN aiming to achieve complete eradication of Barrett’s surface and thus, decreasing the risk of recurrent dysplasia or cancer. The rates of complete remission of neoplasia and metaplasia after completion of endoscopic treatment are 81-92.6% and 75-88.2%, respectively. The aim of this article is to review the principles, techniques, indications, efficacy and safety of this ablative method and surveillance of patients after successful treatment with RFA.


KEY WORDS: Barrett esophagus - Neoplasms - Intestines - Metaplasia

top of page